Research programme: dry eye syndrome therapy - arGentis LLC

Drug Profile

Research programme: dry eye syndrome therapy - arGentis LLC

Alternative Names: ARG 101(T); ARG 102(P); ARG 103; T4DE; T4DE - arGentis

Latest Information Update: 26 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argentis LLC
  • Developer arGentis Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Progesterone receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 26 Nov 2015 Discontinued - Preclinical for Dry eyes in USA (Topical)
  • 24 May 2009 No development reported - Preclinical for Dry eyes in USA (Topical)
  • 16 Jan 2007 arGentis licenses transdermal progesterone in the treatment of Dry Eye Syndrome from Southern College of Optometry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top